key: cord-0744783-j3wzr9zn
authors: Yelin, Dana; Rozen-Zvi, Benaya; Yahav, Dafna; Ben-Dor, Naomi; Steinmetz, Tali; Agur, Timna; Zingerman, Boris; Schneider, Shira; Lichtenberg, Shelly; Ben-Zvi, Haim; Mashraki, Tiki; Rahamimov, Ruth
title: SARS-CoV-2 antibody dynamics among kidney transplant recipients 3 months after BNT162b2 vaccination: a prospective cohort study
date: 2022-01-31
journal: Clin Kidney J
DOI: 10.1093/ckj/sfac031
sha: e4ff23eaba86602bf8ea78ba50b21b3527acb90b
doc_id: 744783
cord_uid: j3wzr9zn

Data regarding immunogenicity of mRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines among kidney transplant recipients in the months following vaccination are lacking. We aimed to investigate humoral immune response at 3–4 months post-vaccination among a cohort of kidney transplant recipients, compared with a control group of dialysis patients. Anti-spike antibodies were tested at 1 and 3–4 months after vaccination. Of 259 kidney transplant recipients tested at a median time of 110 days from second vaccine dose, 99 (38%) were seropositive, compared with 83% (101/122) of control patients. Younger age, better renal function and lower immunosuppression levels were associated with seropositivity. A total of 14% (13/94) of participants seropositive at 1 month became seronegative at follow-up and 11% (18/165) became seropositive. The latter were mainly individuals with higher antibody levels at 1 month. Antibody levels at 3–4 months were significantly reduced in both study groups, although the decline was more pronounced in the control group. Kidney transplant recipients present poor antibody response to mRNA SARS-CoV-2 vaccination, with only 38% seropositive at 3–4 months. Nevertheless, the decay in antibody response over time is modest, and some patients may present delayed response, reaching adequate antibody levels at 3–4 months. Low seropositivity rates in this group call for investigating other immunization strategies.

Inadequate antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccination has been increasingly reported among solid organ transplant (SOT) recipients. Several studies in kidney transplant recipients have shown poor humoral responses up to 1 month following the second mRNA vaccine dose, ranging from 29% to 54% seropositivity [1, 2] . Heart transplant recipients have shown similar response rates [3] , while lung transplant recipients have shown even worse responses (18% seropositivity at 14-21 days following the second vaccine dose) [4] .

Factors associated with reduced humoral response in these studies included increased age, lower glomerular filtration rate (GFR), and type and dose of immunosuppressive medication. Treatment with belatacept or anti-thymocyte globulin (ATG), higher doses of mycophenolic acid; or higher blood levels of calcineurin inhibitors (CNIs) were all associated with lower seropositivity rates [1, 3, 5] .

Among transplant recipients following natural coronavirus disease 2019 (COVID- 19) infection, a few small studies demonstrated similar immediate humoral and cellular response in comparison with healthy controls, soon after the infection [6, 7] . A study following liver transplant recipients over 6 months after natural infection showed lower seropositivity rate at 3 and 6 months when compared with healthy controls, but with a similar decline in seropositivity rates over time (77% seropositivity at 3 months to 63% at 6 months) [8] .

No data are currently available regarding the durability of antibody response following vaccination in transplant recipients. Among healthy subjects, Widge et al. [9, 10] reported elevated antibodies persisting at 90 days and, more recently, 209 days after the second dose of mRNA-1273 (Moderna) vaccine in all 34 participants, despite a slight decrease in levels. Geometric mean titers exceeded those of convalescing non-vaccinated controls. In comparison, Naaber et al. [11] demonstrated a significant decrease in antibody levels among 122 healthy volunteers at 6 and 12 weeks following BNT162b2 vaccine (Pfizer).

In this second stage of a prospective cohort study following kidney transplant recipients after BNT162b2 vaccination, we assessed anti-spike (anti-S) antibody levels at 3 months after the second vaccine dose.

This was a prospective, single center, cohort study, evaluating kidney transplant recipients with functioning grafts that had been vaccinated with two doses of BNT162b2 vaccine, 21 days apart. We included adult recipients (>18 years) receiving first vaccine dose at least 1 month following the transplantation surgery. Participants who had documented infection with COVID-19 at any time prior to vaccination were excluded from the study. The study was conducted according to the declarations of Helsinki and Istanbul, and was approved by the ethic committee of Rabin Medical Center (RMC). The settings, data collection, immunosuppression regimen data and laboratory methods have been previously described (Supplementary data, Supplement 1), as well as outcomes at 2-4 weeks following the second vaccine dose [1] . In this phase of the study, we further tested consenting participants for SARS-CoV-2 antibody levels at ∼3 months after the second vaccine dose. The SARS-CoV-2 IgG II Quant (Abbott©) assay, testing antibodies against the receptor binding domain (RBD) of the spike protein, was used, with level >50 AU/mL considered positive [12] . A control group consisted of dialysis patients, evaluated in the same manner. The rationale for this control group was data from two studies, showing robust antibody response to mRNA vaccines among dialysis patients, similar to a healthy population [13, 14] . Dialysis patients who were treated with immunosuppressant medications were excluded from the control group.

For comparison of continuous variables between groups we used Student's t-test for normally distributed variables and Mann-Whitney U test for non-normally distributed variables. The main outcome of the study was seropositivity for SARS-CoV-2 at 3 months (defined as antibody titer >50 AU/mL) [12] . Secondary outcomes included log-transformed antibody titter (1 was added to the antibody levels and the product was transformed to decimal logarithmic scale) and the change in antibody levels between the two evaluation timepoints.

Univariate and multivariate logistic regression analyses were performed with seropositivity as outcome. Multivariate analysis was done using forward regression with a P-value of 0.05 for inclusion. Variables introduced into the model included: age, gender, body mass index (BMI), donor type, time from transplantation, diabetes status, time from immunization to evaluation, estimated glomerular filtration rate (eGFR), high CNI blood level, mycophenolic acid dose, treatment with ATG (within 6 month before the first vaccine dose), treatment with high-dose corticosteroids (at least 250 mg methyl prednisolone for at least 3 days, within 6 month before the first vaccine dose), treatment with inhibitors of mammalian target of rapamycin (mTOR) and treatment with cyclosporine. For evaluation of the log-transformed antibody titer, we used simple and multiple linear regression analysis. Multivariate analysis was done using forward regression with a P-value of 0.05 for inclusion.

To evaluate antibody dynamics between the first and the second evaluation, we used repeated measure analysis of variance (ANOVA) with the antibody levels at 1 month and 3-4 months as the repeated measures. We evaluated for interactions between the control and the study groups as well as patients' variables in the study group, and the change in antibody levels. All variables with significant interaction (P ≤ 0.05) were introduced into multivariate model. For this analysis, age was divided into two groups (≥50 years versus <50 years) as well as mycophenolic acid dose (no treatment or ≤360 mg versus >360 mg).

We also evaluated the difference between the logtransformed antibody titer at 1 month and 3-4 months. The difference was calculated as log [(1 + Ab 1 month )/(1 + Ab 3-4 months )]. We used simple and multiple linear regression analysis. Multivariate analysis was done using forward regression with P-value of 0.05 for inclusion with all variables mentioned above. All analyses were done using SPSS version 26 (IBM INC, Armonk, NY, USA).

Of the original 308 consenting kidney transplant recipients, 5 had COVID-19 infection during the interval and 1 patient died. Forty-four patients were unavailable for a repeat blood sample during the study period. Two hundred fifty-nine patients (84%) had available measurements of anti-S antibodies at 3-4 months. The control group included 122 dialysis patients from the RMC dialysis units [13] . For baseline characteristics of the study and control groups, see Table 1 and Supplementary data, Table S1 . For the study group, antibody levels were collected at a median time of 110 days [interquartile range (IQR) 98-122 days] from the second vaccine dose. Of the 94 patients who were seropositive at 1 month, 13 (13.8%) turned seronegative; and of the 165 patients seronegative at 1 month, 18 (10.9%) turned seropositive. (See Supplementary data, Figure S2 for visual description of antibody dynamics among these 13 seronegative and 18 seropositive patients.) Overall, of the 259 patients included, 99 (38.2%) were seropositive for anti-S antibodies at 3-4 months, compared with 112/308 (36.4%) at 1 month. Median antibody titer was 17.7 AU/mL (IQR 2.7-156) compared with 15.5 AU/mL (IQR 3.5-163.6) at 1 month. Of the 122 patients in the control group, 101 (82.8%) were seropositive (P < 0.001 versus study group) at 3-4 months, compared with 114/122 (93.4%) at 1 month. The values for antibody levels and log transformed antibody levels at 1 and 3-4 months for the study and control groups are presented in Table 2 and Figure 1 . The distribution of log-transformed difference between anti-S antibody levels at 1 and 3-4 months was normal and is depicted in Figure 2 . 

On univariate and multivariate analyses, the variables that were associated with anti-S positivity in the study group included younger age {odds ratio (OR) 1 Table 3 . This was also shown in a second analysis using the log transformed anti-S antibody levels as a continuous variable (see Supplementary data, Table S3 ).

Similar results were also found on additional analyses including only the 239 patients (92.3%) treated with tacrolimus, performed using tacrolimus level as a continuous variable. The results of this analysis are detailed in Supplementary data, Tables S4 and S5.

Of the 165 seronegative patients at 1 month, 18 (10.9%) became seropositive. Median antibody levels at 1 month were 29 AU/mL (IQR 14-42 AU/mL) and increased to a median of 80 AU/mL (IQR 57-139 IU/mL) at 3 months. In univariate logistic regression analysis, higher antibody levels at 1 month [OR 1.107/AU/mL (95% CI 1.065-1.152), P < 0.001] and eGFR above 60 mL/min/1.73 m 2 [OR 4.105 (95% CI 1.389-12.13), P = 0.011] were associated with seroconversion at 3 months. These findings remained significant on multivariate analysis, as well as younger age, which was also significantly associated with seroconversion [OR 1.058 (95% CI 1.008-1.109), P = 0.022]. The results of the analysis are presented in Supplementary data, Table S6 .

Of the 94 seropositive patients at 1 month, 13 (13.8%) became seronegative. Median antibody levels at 1 month were 92 AU/mL (IQR 67-184 AU/mL) decreased to a median of 26 AU/mL (IQR 18-36 IU/mL) at 3 months. In univariate logistic regression analysis, these 13 patients were at longer duration from transplantation, with lower BMI, less likely to be treated with tacrolimus and had lower antibody levels at 1 month. This sample size was too small to perform multivariate analysis (13 patients) (see Supplementary data, Table S2 ).

Anti-S antibody levels at 1 and 3 months for the study and control groups are presented in Table 2 and Figure 1 . The anti-S antibody levels at 3-4 months were significantly reduced in the study groups (P = 0.007) and the control group (P < 0.001) compared with at 1 month. Similar findings were demonstrated in an analysis including only patients seropositive at 1 month (Supplementary data, Figure S1 and Table S7 ). The reduction in Ab-antibodies; ATG-antithymocyte globulin; BMI-body mass index; CNI-calcineurin; CS-corticosteroids; DM-diabetes mellitus; eGFR-estimated glomerular filtration rate; mTOR-mechanistic target of rapamycin; SD-standard deviation.

levels was significantly lower in the study versus control groups (P < 0.001).

Antibody level decline over time was associated with GFR <60 mL/min/1.73 m 2 (P = 0.028), diabetes mellitus (P = 0.026), no treatment or low dose of mycophenolic acid (P < 0.001) and positive antibody response at 1 month (P = 0.006) on univariate and multivariate analysis. This was shown using repeated measures ANOVA and validated on evaluation of factors associated with the log-transformed difference in antibody levels between 1 and 3-4 months (Table 4 and Supplementary data, Table S8 , respectively). Treatment with mTOR inhibitors, which had no interaction with antibody level change by univariate analysis, significantly interacted with antibody decline when introduced into the multivariate model (P = 0.014). The results of the repeated measure ANOVA are detailed in Table 4 .

In this cohort of 259 kidney transplant recipients 3-4 months following second dose of mRNA vaccination, we demonstrated that antibody response remained low (38%) at similar rates to those observed at 1 month. Among seropositive patients at 1 month, ∼14% had declining antibodies to a level of seronegativity at 3 months. At the same time, ∼12% of patients seronegative at 1 month seroconverted to positive. This conversion to seropositivity was more likely in younger patients, those with increased eGFR and those who had higher antibody levels at 1 month. For the entire cohort, antibody levels declined over time, but at a slower rate in comparison with the control group of dialysis patients.

The findings of similar seropositivity rates with a modest decline at 3 months are in accordance with current knowledge on the immune response to natural SARS-CoV-2 infection. In patients after natural COVID-19 infection, studies demonstrate either sustained levels [15, 16] or progressive modest decline of IgG levels to spike protein (25% decrease by day 105 and 46% by Day 115 for anti-RBD antibodies in one study) [17] . Seropositivity rates remain high months after natural infection, reported to be 88-90% after 6-8 months [17] [18] [19] . Neutralization antibody dynamics is reported to be similar to that of anti-RBD antibodies [17, 18] .

A decline in antibody titer is expected in the weeks following vaccination in general. Such decline has also been demonstrated among immunocompetent individuals after mRNA COVID-19 vaccines. Among healthcare workers, a reduction in IgG levels has been observed each month following the second BNT162b2 dose, as well as a decline in neutralizing antibody titers, decreasing by a factor of 3.9 at 3 months [20] . It has also been demonstrated that anti-RBD antibody titers decline faster than antispike antibody titers, which were more stable over time [9, 21, 22] . Naaber et al. found a decline in anti-RBD from peak mean levels of 26 928 AU/mL at 1 week after the second mRNA vaccine dose to 13 943 AU/mL at 6 weeks (45% decrease), and to 5702 AU/mL at 12 weeks after the second dose (77% decrease) among 90 healthy individuals. These levels, however, remained significantly higher compared with patients recovered from natural infection. Older age was associated with a decreased antibody titer in each time point tested in this study [11] . Similarly,

McDade et al. [23] reported a drop of 50% in anti-RBD IgG levels at 3 months after vaccination compared with peak levels measured after the second vaccine dose. In a group of 142 hemodialysis patients, Berar-Yanay et al. [24] demonstrated a response rate of 94% 1 month after second dose, declining to 78% at 3 months after the second dose of BNT162b2.

Among kidney transplant recipients, Boyarsky et al. [25] recently reported antibody response at 3 months after two-dose mRNA vaccination. In this study, among 75 patients with lowpositive titers at 1 month, 35 (47%) became highly positive at 3 months, indicating that a delayed response may be possible, as suggested by our results. In this study, overall 43% of patients had an increase in titer from 1 to 3 months, 35% had a decrease and 21% remained stable. Four percent of seropositive patients at 1 month became seronegative at 3 months, lower than the 14% in our study [25] . An additional recent study including 312 SOT recipients demonstrated consistent results of relatively stable antibodies over time. At ∼1 month following a second dose of mRNA vaccine, 63% were seropositive; at ∼3 months, 72% were seropositive; and at 6 months, 72% as well. Seven percent of seropositive patients at 1 month became seronegative at 6 months [26] .

Regarding patients who were seronegative and turned seropositive, we cannot rule out a delayed antibody response for SOT recipients, as also suggested by the two studies described above [25, 26] . Peak antibody response has been previously demonstrated at between Day 15 and 45 after natural infection [17, 22] . We were unable to explain why this was more likely in younger patients and those with higher eGFR; however, it seems reasonable that patients with some antibody response (negative according to test interpretation, but levels above zero) were more likely to mount antibody response at a later stage. Nevertheless, it is still possible that some of the patients became seropositive due to test limitations and margin of error.

To some extent, serum antibodies are a surrogate marker for vaccine effectiveness in immunocompromised patients. Annual anti-HBs (hepatitis B surface antibodies) titers monitoring is recommended for kidney transplant recipients for decisions on revaccination [27] . Monitoring antibody response to SARS-CoV-2 vaccine may also serve as a potential tool to identify the need and timing of potential revaccination. Using this surrogate, we assume that the vast majority of kidney transplant recipients seropositive at 1 month are still protected at 3 months. As the strategy of administrating a third mRNA dose is evolving [28] , these findings support 1 month as a reasonable time point for serological assessment for decision-making.

This study has several limitations. The importance of waning immunity, specifically antibody levels, in protecting against disease is still uncertain. Moreover, in our study, we did not test neutralizing antibodies. However, high correlation between anti-RBD antibodies and neutralizing antibodies has been documented [22, 29] , and even modest levels of neutralizing antibodies have been demonstrated to provide protection against COVID-19 [18] for the long term. In addition, detectable antibodies months after acute COVID-19 have been shown to be associated with protection against re-infection [30] . Thus, we assume that seropositivity at 1-3 months represents, at least to some extent, protection against infection. Another limitation in this regard is that no tests for T-cell response to vaccine were conducted in this study.

In summary, we document similarly low rates of antibody response at 3 months and 1 month following mRNA vaccine in kidney transplant recipients, with 14% of seropositive patients at

Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study

Antibody response to 2-dose sars-cov-2 mrna vaccine series in solid organ transplant recipients

Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients-a prospective cohort study

Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine

Immunogenicity and reactogenicity after SARS-CoV-2 mRNA vaccination in kidney transplant recipients taking belatacept

The magnitude and functionality of SARS-CoV-2 reactive cellular and humoral immunity in transplant population is similar to the general population despite immunosuppression

Evidence of potent humoral immune activity in COVID-19-infected kidney transplant recipients

SARS-CoV-2 antibody dynamics among kidney transplant recipients 3 months after BNT162b2 vaccination

Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients

Durability of responses after SARS-CoV-2 mRNA-1273 vaccination

Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for covid-19

Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study

SARS-CoV-2 IgG II Quant

Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients-a prospective cohort study

High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients

Humoral immune response to SARS-CoV-2 in iceland

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in patients with COVID-19

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: serial cross-sectional studies of 365,000 adults

Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history

Waning humoral response 3 to 6 months after vaccination with the SARS-COV-2 BNT162b2 mRNA vaccine in dialysis patients

Antibody kinetics and durability in SARS-CoV-2 mRNA vaccinated solid organ transplant recipients

Six-month antibody kinetics and durability in SARS-CoV-2 mRNA vaccinated solid organ transplant recipients

IDSA clinical practice guideline for vaccination of the immunocompromised host

Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses

BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics : a prospective, single-centre, longitudinal cohort study in health-care workers

Antibody status and incidence of SARS-CoV-2 infection in health care workers

This study was performed in collaboration with the Israeli Ministry of Health. The authors wish to thank Ehud Ben-Dor, Irit Schnitzer and Michal Nachtomy-Disatnik for their contribution to this study.

Supplementary data are available at ckj online.

The authors of this manuscript have no conflicts of interest to disclose. The results presented in this article have not been published previously in whole or part.

The original data from this study may be available upon reasonable request to the corresponding author